Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Renal Insufficiency 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Hematologic Diseases 1Blood Protein Disorders 1

Interventions

Dexamethasone 13Bortezomib 8Cyclophosphamide 5Lenalidomide 4pomalidomide 3isatuximab 3Calcium Dobesilate 3Thalidomide 2Kidney Transplantation 2melflufen 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1belantamab mafodotin 1auricularum 1Zoledronic Acid 1Whole-Body Irradiation 1Tablets 1Ranitidine 1Plasmapheresis 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Drug Therapy 1Doxorubicin 1Diphenhydramine 1Data Collection 1Cyclosporine 1Bendamustine Hydrochloride 1BHQ880 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Insufficiency × Ranitidine × Plasma cell × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡